biotech-deals

Alnylam Bet $2 Billion on AI-Designed RNAi. The Check It Actually Wrote Was $30 Million.

Alnylam paid Inceptive Nucleics $30 million up front, with up to $2 billion in milestones tied to outcomes the rest of AI drug discovery has spent a decade failing to deliver.